The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
作者信息
Floriano Idevaldo, Silvinato Antônio, Bernardo Wanderley Marques
机构信息
Cooperativa Baixa Mogiana, Evidence-Based Medicine - Mogi-Guaçu (SP), Brazil.
Brazilian Medical Association, Evidence-Based Medicine - São Paulo (SP), Brazil.
出版信息
Rev Assoc Med Bras (1992). 2023 May 15;69(4):e2023D694. doi: 10.1590/1806-9282.2023D694. eCollection 2023.
Abstract
摘要
相似文献
1
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Rev Assoc Med Bras (1992). 2023 May 15;69(4):e2023D694. doi: 10.1590/1806-9282.2023D694. eCollection 2023.
2
Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
J Psychiatr Res. 2021 May;137:426-436. doi: 10.1016/j.jpsychires.2021.03.009. Epub 2021 Mar 16.
3
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
CNS Drugs. 2021 Oct;35(10):1069-1079. doi: 10.1007/s40263-021-00851-8. Epub 2021 Sep 7.
4
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
J Clin Psychiatry. 2020 May 12;81(3):19m13191. doi: 10.4088/JCP.19m13191.
5
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
J Clin Psychiatry. 2010 Dec;71(12):1605-11. doi: 10.4088/JCP.09m05327blu. Epub 2010 Jul 13.
6
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Eur Neuropsychopharmacol. 2022 Apr;57:88-104. doi: 10.1016/j.euroneuro.2022.02.004. Epub 2022 Feb 23.
7
The rapid anti-suicidal ideation effect of ketamine: A systematic review.
Prev Med. 2021 Nov;152(Pt 1):106524. doi: 10.1016/j.ypmed.2021.106524. Epub 2021 Sep 16.
8
Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
Aust N Z J Psychiatry. 2020 Jan;54(1):29-45. doi: 10.1177/0004867419883341. Epub 2019 Nov 15.
9
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
J Affect Disord. 2019 Jan 15;243:516-524. doi: 10.1016/j.jad.2018.09.037. Epub 2018 Sep 17.
10
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
BMC Psychiatry. 2022 Nov 30;22(1):744. doi: 10.1186/s12888-022-04388-y.
引用本文的文献
1
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).
J Pers Med. 2025 Apr 21;15(4):161. doi: 10.3390/jpm15040161.
2
Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review.
Transl Psychiatry. 2025 Feb 6;15(1):44. doi: 10.1038/s41398-025-03255-0.
3
Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial.
BMC Pharmacol Toxicol. 2023 Nov 23;24(1):66. doi: 10.1186/s40360-023-00705-7.
4
The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.
Brain Sci. 2023 Oct 22;13(10):1494. doi: 10.3390/brainsci13101494.
本文引用的文献
1
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Arch Womens Ment Health. 2022 Apr;25(2):313-326. doi: 10.1007/s00737-021-01185-6. Epub 2022 Jan 1.
2
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
BMC Psychiatry. 2021 Oct 25;21(1):526. doi: 10.1186/s12888-021-03538-y.
3
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.
Neuropsychiatr Dis Treat. 2021 Jul 15;17:2347-2357. doi: 10.2147/NDT.S314874. eCollection 2021.
4
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
J Clin Psychiatry. 2021 Jul 20;82(4):20m13800. doi: 10.4088/JCP.20m13800.
5
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
J Psychopharmacol. 2021 Aug;35(8):890-900. doi: 10.1177/02698811211013579. Epub 2021 Jul 9.
6
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
J Affect Disord. 2021 Oct 1;293:285-294. doi: 10.1016/j.jad.2021.06.032. Epub 2021 Jun 24.
7
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Mol Psychiatry. 2022 Jan;27(1):559-573. doi: 10.1038/s41380-021-01121-1. Epub 2021 May 7.
8
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
9
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.
10
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):22-31. doi: 10.1093/ijnp/pyaa068.
Zotero 插件